Up 19.2%, Is Viking Therapeutics Stock Still a Buy?
Viking Therapeutics (NASDAQ: VKTX), a small-cap pre-revenue biotech, saw its shares jump by an eye-catching 19.2% in response to its third-quarter earnings report, released ahead of the opening bell on Tuesday.
Can this clinical-stage drugmaker keep rolling higher, or should shareholders take this opportunity to jump ship? After all, Viking's shares have been one of the worst performing biotech stocks over the past 12 months, and there's no guarantee that it will hold yesterday's gains on a forward-looking basis. Let's break down the biotech's Q3 earnings report to consider whether investors should stay the course.
Image source: Getty Images.
Source Fool.com
